Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Osteoporotic fracture prevention guidance

  • Comment

Postmenopausal women at increased risk of osteoporotic fractures should be treated with denosumab (Prolia), if treatment with the oral bisphosphonates alendronate, risedronate or etidronate is unsuitable, according to draft guidance from NICE.

Denosumab is given by injection twice a year and works by reducing bone breakdown and increasing bone mass and strength.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.